Treatment
Treatment
Neurological pain and migraines affect 1 in 9 people – that’s over 33 million people in the US alone, of which 75 percent are women. Beyond simply the debilitating nature of neurological pain, the economic implications are staggering, costing the US taxpayer approximately $13 billion in missed work or reduced productivity in 2009.
.gif)
Editor's Choice
EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, indicated for the management of chronic moderate to severe pain, contain extended-release pellets of...
Cluster headache (CH) is, by neurological standards, a relatively common condition that affects about one in 1,000 people,1 although compared with other more common primary headaches such as...
Most recent articles
Opioids are a treatment option for moderate to severe pain in appropriately selected patients who have not responded to non-opioid therapies.1...
Cluster headache (CH) is, by neurological standards, a relatively common condition that affects about one in 1,000 people,1 although compared with...
Migraine Pathophysiology In recent years, significant advances have been made in the understanding of migraine pathophysiology. Although the exact...
The diagnostic problem most often encountered is the difficulty of discriminating between TTH and mild migraines. Measures towards attaining a...
General Diagnostic Matters Concerning Trigeminal Autonomic Cephalalgias Recently, some important diagnostic matters have arisen around TACs. These...
